News

Medical nanoparticles transport drugs for local treatment of lung cancer

6 Mar 2015
Medical nanoparticles transport drugs for local treatment of lung cancer

Nanoparticles can function as carriers for medicines to combat lung cancer, according to the latest research from Germany.

Working in a joint project, scientists from the Helmholtz Zentrum München and the Ludwig-Maximilians-Universität in Munich have developed nanocarriers that site-selectively release medicines/drugs at the tumour site in human and mouse lungs.

The scientists reported in ACS Nano that this approach led to a significant increase in the effectiveness of current cancer medicines in lung tumour tissue.

Nanoparticles are extremely small particles that can be modified for a variety of uses in the medical field.

For example, nanoparticles can be engineered to be able to transport medicines specifically to the disease site while not interfering with healthy body parts.

The Munich scientists have developed nanocarriers that only release the carried drugs in lung tumour areas. 

Tumour specific proteins were used to release drugs from the nanocarriers

Tumour tissue in the lung contains high concentrations of certain proteases, which are enzymes that break down and cut specific proteins.

The scientists took advantage of this by modifying the nanocarriers with a protective layer that only these proteases can break down, a process that then releases the drug.

Protease concentrations in the healthy lung tissue are too low to cleave this protective layer, and so the medicines stay protected in the nanocarrier.

"Using these nanocarriers we can very selectively release a drug such as a chemotherapeutic agent specifically at the lung tumour," reports research group leader Meiners.

"We observed that the drug's effectiveness in the tumour tissue was 10 to 25 times greater compared to when the drugs were used on their own. At the same time, this approach also makes it possible to decrease the total dose of medicines and consequently to reduce undesirable effects."

Further studies will now be directed to examine the safety of the nanocarriers in vivo and verify the clinical efficacy in an advanced lung tumour mouse model.

Source: German Research Centre for Environmental Health